Review of erlotinib in the treatment of advanced non-small cell lung cancer

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 335-346

  Ganjoo, Kristen N ^a   Wakelee, Heather ^b  

^a Palo Alto VA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Non small cell lung cancer

Indexed keywords

EID: 63149090545     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Bae NC, Chae MH, Lee MH, et al. 2007. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet, 173:107-13.
2. Baselga J. 2000. New technologies in epidermal growth factor receptortargeted cancer therapy:an overview of novel therapeutic agents in development. Signal, 1:12-21.
3. Bezjak A, Tu D, Seymour L, et al. 2006. Symptom improvement in lung cancer patients treated with erlotinib:quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 24:3831-7.
4. Bonner JA, Harari PM, Giralt J, et al. 2004. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck:A phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol, 23:5507.
5. Bunn PA, Dziadziuszko R, Varella-Garcia M, et al. 2002. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res, 12:3652-6.
6. Cappuzzo F, Ligorio C, Janne P, et al. 2007. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phosphor-Akt-positive or never smoker patients with advanced non-small cell lung cancer: The ONCOBELL trial. J Clin Oncol, 25:2248-55.
7. Cappuzzo F, Hirsch FR, Rossi E, et al. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst, 97:643-55.
8. Chan TO, Rittenhouse SE, Tsichlis PN. 1999. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Ann Rev Biochem, 68:965-1014.
9. Ciardiello F, Tortora G. 2001. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res, 7:2958-70.
10. Cunningham D, Humblet Y, Siena S, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351:337-45.
11. Daniele L, Macri L, Schena M, et al. 2007. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization /chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther, 6:1223-9.
12. Davies AM, Hesketh PJ, Beckett L, et al. 2007. Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC):Overcoming hypothesized antagonism. J Clin Oncol, Proc ASCO, 25, 18S:abst# 7618.
13. Davies AM, Lara PN, Lau DH, et al. 2005. Intermittent erlotinib in combination with docetaxel (DOC):Phase I schedules designed to schieve pharmacodynamic separation. J Clin Oncol, Proc ASCO, 23, 16S: abst# 7038.
14. Delbaldo C, Michiels S, Syz N, et al. 2004. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer. JAMA, 292:470-84.
15. Eberhard DA, Johnson BE, Amler LC, et al. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23:5900-9.
16. Eichelbaum M, Burk O. 2001. CYP3A genetics in drug metabolism. Nature Med, 7:285-7.
17. Engebraaten O, Bjerkvig R, Pedersen PH, et al. 1993. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro. Int J Cancer, 53:209-14.
18. Engelman JA, Zejnullahu K, Mitsudomi T, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activationg ERBB3 signaling. Science, 316:1093-43.
19. Fidias P, Dakhil S, Lyss A, et al. 2007. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer:Updated report with survival. J of Clin Oncol, ASCO Proc, 25, No. 18S:abst# LBA7516.
20. Fossella F, DeVore R, Kerr R, et al. 2000. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18:2354-62.
21. Franklin WA, Veve R, Hirsch FR, et al. 2002. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol, 29(Suppl 4):3-14.
22. Fukuoka M, Yano S, Giaccone G, et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) corrected. J Clin Oncol, 21:2237-46.
23. Gatzemeier U, Ardizzoni A, Horwood K, et al. 2007a. Erlotinib in non-small cell lung cancer (NSCLC):Interim safety analysis of the TRUST study. J Clin Oncol, Proc ASCO, 25, 18S:abstr# 7645.
24. Gatzemeier U, Pluzanska A, Szczesna A, et al. 2007b. Phase III study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced non-small cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25:1545-52.
25. Giaconne G, Herbst RS, Manegold C, et al. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol, 22:777-84.
26. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. 2006. Erlotinib for frontline treatment of advanced non-small cell lung cancer:a phase II study. Clin Cancer Res, 12:6049-55.
27. Gill GN, Kawamoto T, Cochet C, et al. 1984. Monoclonal antiepidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factorstimulated tyrosine protein kinase activity. J Biol Chem, 259:7755-60.
28. Guengerich FP. 1995. Oritz de Montellano PR. (Ed.), Cytochrome P450: Structure, Echanism, and Biochemistry. New York: Plenum Press, pp. 73-536.
29. Gumerlock PH, Pryde BJ, Kimura T, et al. 2003. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung cancer (NSCLC). J Clin Oncol, Proc ASCO, 22:abst# 2661.
30. Hanna N, Shepherd FA, Fossella FV, et al. 2004. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22:1589-97.
31. Herbst RS, Prager D, Hermann R, et al. 2005a. TRIBUTE:a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol, 23:5892-9.
32. Herbst RS, Johnson DH, Mininberg E, et al. 2005b. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol, 23:2544-55.
33. Herbst RS. 2004. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 59:21-6,
34. Hidalgo M, Siu LL, Nemunaitis J, et al. 2001. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol, 19:3267-79.
35. Hirata A,Ogawa S, Kometani T, et al. 2002. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res, 62:2554-60.
36. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. 2007. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small cell lung cancer patients treated with gefitinib. Ann Oncol, 18:752-60.
37. Hirsch FR, Varella-Garcia M, Bunn PA, et al. 2003. Epidermal growth factor receptor in non-small cell lung carcinomas:correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 21:3798-807.
38. Inoue A, Suzuki T, Fukuhara T, et al. 2006. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutation. J Clin Oncol, 24:3340-6.
39. Jackman DM, Yeap BY, Lindeman NI, et al. 2007. Phase II clinical trial of chemotherapy-naive patients or = 70 years of age treated with erlotinib for advanced non-small cell lung cancer. J Clin Oncol, 25:760-6.
40. Jackman DM, Yeap BY, Sequist LV, et al. 2006. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res, 12:3908-14.
41. Janne PA, Engelman JA, and Johnson BE. 2005. Epidermal growth factor receptor mutations in non-small cell lung cancer:Implications for treatment and tumor biology. J Clin Oncol, 23:3227-34.
42. Jatoi A, Rowland K, Sloan JA, et al. 2007. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol, Proc ASCO, 25, 18S:abst# LBA9006.
43. Journagan S, Obadiah J. 2006. An acneiform eruption due to erlotinib: Prognostic implications and management. J Am Academy of Derm, 54:358-60.
44. Kelly K, Chansky K, Gaspar LE, et al. 2007. Updated analysis of SWOG 0023:A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol, Proc ASCO, 25, 18S:abst# 7513.
45. Kolesar J, Brahmer J, Lee J, et al. 2007. Final results of ECOG 3503:A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, Proc ASCO, 25, 18S:abst# 7588.
46. Kris MG, Natale RB, Herbst RS, et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290:2149-58.
47. Laack E, Schneider C, Gutjahr T, et al. 2007. Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer. J Clin Oncol, Proc ASCO, 25, 18S:abst# 7651.
48. Lee M, Seo C, Kim S, et al. 2004. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (zd1839), an inhibitor of epidermal growth factor. Acta Derm Veneroel, 84:23-6.
49. Li J, Zhao M, He P, et al. 2007. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res, 13:3731-7.
50. Lilenbaum R, Axerold R, Thomas S, et al. 2006. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. J Clin Oncol, Proc ASCO, 24, 18S:abst# 7022.
51. Luu M, Lai SE, Patel J, et al. 2007. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed, 23:42-5.
52. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med, 350:2129-39.
53. Manegold C, von Pawel J, Zatloukal P, et al. 2007. The BO17704 study group. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC):BO17704. J Clin Oncol, Proc ASCO, 25, 18S:abst# LBA7514.
54. Miller VA, Zakowski M, Riely GJ, et al. 2006. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. J of Clin Oncol, Proc ASCO, 24, 18S:abst# 7003.
55. Milton DT, Azzoli CG, Heelan RT, et al. 2006. A phase I/II study of weekly high dose erlotinib in previously treated patients with non-small cell cancer. Cancer, 107:1034-41.
56. Moore MJ, Goldstein D, Hamm J, et al. 2007. Erlotinib Plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960-66.
57. Mounawar M, Mukeria A, Calvez FL, et al. 2007. Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in nonsmall cell Lung Cancers in Relation to Smoking History. Cancer Res, 67:5667-72.
58. Natale RB, Bodkin D, Govindan R, et al. 2006. ZD6474 versus gefitinib in patients with advanced NSCLC:Final results from a two-part, double blind, randomized phase II trial. J Clin Oncol, Proc ASCO, 24, 18S:abst# 7000.
59. Paez JG, Janne PA, Lee JC, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304:1497-500.
60. Pao W, Miller V, Zakowski M, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101:13306-11.
61. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. 2006. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol, ASCO proc, 24 (18S)# 7020.
62. Perez-Soler R, Chachoua A, Hammond LA, et al. 2004. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol, 22:3238-47.
63. Petit AM, Rak J, Hung MC, et al. 1997. Neutralizing antibodies against epidermal growth factor and ErbB2-neu receptor tyrosine kinase downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol, 151:1523-30.
64. Riely GJ, Rudin CM, Kris MG, et al. 2007. A randomized phase II trial comparing pulsed erlotinib before or after carboplatin in patients with stage IIIB or IV non-small cell lung cancer. J Clin Oncol, Proc ASCO, 25, 18S:abst# 7619.
65. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al. 2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22:1201-8.
66. Sandler A, Gray R, Perry MC, et al. 2006a. PaclitaxelCarboplatin Alone or with Bevacizumab for non-small cell Lung Cancer. N Eng J Med, 355:2542-50.
67. Sandler A, Herbst R. 2006b. Combining targeted agents:blocking the epidermal growth factor and vascular endothelial growth factor. Clin Cancer Res, 12:4421s-25s.
68. Sato JD, Kawamoto T, Le AD, et al. 1983. Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol Biol Med, 1:511-2.
69. Schiller JH, Harrington D, Belani CP, et al. 2002. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Eng J Med, 346:92-8.
70. Schneider C, Schott-von Romer K, Gutz S, et al. 2007. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). J Clin Oncol, Proc ASCO, 25, 18S:abst# 7674.
71. Sequist LV, Joshi VA, Janne PA, et al. 2007. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. The Oncologist, 12:90-8.
72. Shepherd FA, J. Rodrigues Pereira, Ciuleanu T, et al. 2005. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med, 353:123-32.
73. Shepherd F, Dancey J, Ramlau R, et al. 2000. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18:2095-103.
74. Taguchi F, Solomon B, Gregorc V, et al. 2007. Mass spectrometry to classify non-small cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors:A multicohort cross-institutional study. J Natl Cancer Inst, 99:838-46.
75. Tam IYS, Chung LP, Suen WS, et al. 2006. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in non-small cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features. Clin Cancer Res, 12:1647-53.
76. Thatcher N, Chang A, Parikh P, et al. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer:results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366:1527-37.
77. Tsao MS, Sakurada A, Cutz JC, et al. 2005. Erlotinib in lung cancermolecular and clinical predictors of outcome. N Engl J Med, 353:133-44.
78. Vikis H, Sato M, James M, et al. 2007. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res, 67:4665-70.